Marcia Belvin - Sep 26, 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin
Stock symbol
CTMX
Transactions as of
Sep 26, 2025
Transactions value $
$0
Form type
4
Date filed
9/30/2025, 06:37 PM
Previous filing
Jun 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BELVIN MARCIA SVP, Chief Scientific Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO /s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin 2025-09-30 0001970752

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +36.3K $0.00 36.3K Sep 26, 2025 Common Stock 36.3K $2.90 Direct F1
transaction CTMX Performance Stock Units (PSUs) Award $0 +18.2K $0.00 18.2K Sep 26, 2025 Common Stock 18.2K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F2 Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.